TY - JOUR
T1 - Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era
T2 - A survey of the European Cooperative Group for Blood and Marrow Transplantation
AU - Sanz, M. A.
AU - Labopin, M.
AU - Gorin, N. C.
AU - de la Rubia, J.
AU - Arcese, W.
AU - Meloni, G.
AU - Bacigalupo, A.
AU - Alessandrino, P.
AU - Carreras, E.
AU - Iriondo, A.
AU - Novitzky, N.
AU - Jacobs, P.
AU - Bandini, G.
AU - Lo-Coco, F.
AU - Frassoni, F.
AU - Rocha, V.
PY - 2007/4
Y1 - 2007/4
N2 - We performed a survey of the European Cooperative Group for Blood and Marrow Transplantation to analyze the outcome of 625 acute promyelocytic leukemia (APL) patients transplanted with auto- or allogeneic-hematopoietic stem cell transplantation (autoHSCT, alloHSCT) after 1993, in first (CR1) or in second complete remission (CR2). Leukemia-free survival (LFS) at 5 years in CR1 was 69% for 149 patients autografted and 68% for 144 patients allografted, whereas in CR2, LFS was 51% in 195 autoHSCT and 59% in 137 alloHSCT recipients, respectively. In the group of autoHSCT for CR1 (n=149), higher relapse incidence (RI) was associated with shorter time from diagnosis to transplant (47 years), whereas for CR2, longer time from diagnosis to transplant (>18 months) was associated with increased LFS and decreased RI. In the alloHSCT group for CR1 (n=144), age (
AB - We performed a survey of the European Cooperative Group for Blood and Marrow Transplantation to analyze the outcome of 625 acute promyelocytic leukemia (APL) patients transplanted with auto- or allogeneic-hematopoietic stem cell transplantation (autoHSCT, alloHSCT) after 1993, in first (CR1) or in second complete remission (CR2). Leukemia-free survival (LFS) at 5 years in CR1 was 69% for 149 patients autografted and 68% for 144 patients allografted, whereas in CR2, LFS was 51% in 195 autoHSCT and 59% in 137 alloHSCT recipients, respectively. In the group of autoHSCT for CR1 (n=149), higher relapse incidence (RI) was associated with shorter time from diagnosis to transplant (47 years), whereas for CR2, longer time from diagnosis to transplant (>18 months) was associated with increased LFS and decreased RI. In the alloHSCT group for CR1 (n=144), age (
UR - http://www.scopus.com/inward/record.url?scp=34247274207&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247274207&partnerID=8YFLogxK
U2 - 10.1038/sj.bmt.1705620
DO - 10.1038/sj.bmt.1705620
M3 - Article
C2 - 17322930
AN - SCOPUS:34247274207
SN - 0268-3369
VL - 39
SP - 461
EP - 469
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 8
ER -